Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS® Crohn's Prognostic test. This novel and unique diagnostic represents a significant advance in the Prometheus Inflammatory Bowel Disease (IBD) franchise of diagnostic and prognostic tests, and complements the market-leading PROMETHEUS® IBD Serology 7.
The PROMETHEUS® Crohn's Prognostic test combines six serologic markers and three genetic mutation markers to provide physicians with a personalized serogenetic profile for their patients. This will help enable physicians to quantify these patients' risk of developing disease complications and is designed to provide information to assist physicians in determining optimal treatment strategies for their Crohn's patients.
"The Prometheus Crohn's Prognostic allows clinicians to use serologic and genetic information in order to stratify patients relative to their risk of disease progression," said Marla Dubinsky, M.D., Director of the IBD Pediatric Center at Cedars Sinai Medical center in Los Angeles. "This approach may help physicians develop a more individualized treatment plan for each patient and help them explain the risk/benefit ratio of these treatments to their patients and their families."
Understanding the role of genetic variants in male infertility